Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nat Med. 2023 Jan;29(1):49-58. doi: 10.1038/s41591-022-02160-z. Epub 2023 Jan 16.
Recently, advances in wearable technologies, data science and machine learning have begun to transform evidence-based medicine, offering a tantalizing glimpse into a future of next-generation 'deep' medicine. Despite stunning advances in basic science and technology, clinical translations in major areas of medicine are lagging. While the COVID-19 pandemic exposed inherent systemic limitations of the clinical trial landscape, it also spurred some positive changes, including new trial designs and a shift toward a more patient-centric and intuitive evidence-generation system. In this Perspective, I share my heuristic vision of the future of clinical trials and evidence-based medicine.
最近，可穿戴技术、数据科学和机器学习的进步开始改变循证医学，为下一代“深度”医学的未来带来了诱人的前景。尽管基础科学和技术取得了惊人的进步，但医学主要领域的临床转化却滞后不前。虽然 COVID-19 大流行暴露了临床试验领域固有的系统局限性，但它也推动了一些积极的变化，包括新的试验设计和向更以患者为中心和直观的证据生成系统的转变。在这篇观点文章中，我分享了我对临床试验和循证医学未来的启发式愿景。
